These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
71 related articles for article (PubMed ID: 7652582)
1. The natural history of chronic myelogenous leukemia in the interferon era. Giralt S; Kantarjian H; Talpaz M Semin Hematol; 1995 Apr; 32(2):152-8. PubMed ID: 7652582 [TBL] [Abstract][Full Text] [Related]
2. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease. Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886 [TBL] [Abstract][Full Text] [Related]
3. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. Kantarjian HM; Talpaz M; O'Brien S; Smith TL; Giles FJ; Faderl S; Thomas DA; Garcia-Manero G; Issa JP; Andreeff M; Kornblau SM; Koller C; Beran M; Keating M; Rios MB; Shan J; Resta D; Capdeville R; Hayes K; Albitar M; Freireich EJ; Cortes JE Clin Cancer Res; 2002 Jul; 8(7):2177-87. PubMed ID: 12114418 [TBL] [Abstract][Full Text] [Related]
4. Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Kantarjian HM; O'Brien S; Cortes JE; Shan J; Giles FJ; Rios MB; Faderl SH; Wierda WG; Ferrajoli A; Verstovsek S; Keating MJ; Freireich EJ; Talpaz M Cancer; 2003 Feb; 97(4):1033-41. PubMed ID: 12569603 [TBL] [Abstract][Full Text] [Related]
5. Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Kantarjian H; Talpaz M; O'Brien S; Giles F; Rios MB; White K; Garcia-Manero G; Ferrajoli A; Verstovsek S; Wierda W; Kornblau S; Cortes J Cancer; 2003 May; 97(9):2225-8. PubMed ID: 12712475 [TBL] [Abstract][Full Text] [Related]
6. The impact of the combination of baseline risk group and cytogenetic response on the survival of patients with chronic myeloid leukemia treated with interferon alpha. Hasford J; Pfirrmann M; Shepherd P; Guilhot J; Hehlmann R; Mahon FX; Kluin-Nelemans HC; Ohnishi K; Steegmann JL; Thaler J Haematologica; 2005 Mar; 90(3):335-40. PubMed ID: 15749665 [TBL] [Abstract][Full Text] [Related]
7. [Initial treatment of chronic myelogenous leukemia--interferon or bone marrow transplantation]. Urabe A Gan To Kagaku Ryoho; 1999 Sep; 26(10):1381-6. PubMed ID: 10500523 [TBL] [Abstract][Full Text] [Related]
8. Alpha interferon: progress and perspectives in the biotherapy of chronic myelogenous leukemia. Habermann TM Oncol Nurs Forum; 1989; 16(6 Suppl):8-11. PubMed ID: 2687814 [TBL] [Abstract][Full Text] [Related]
9. Multicenter prospective study of interferon-alpha and conventional chemotherapy versus bone marrow transplantation for newly diagnosed patients with chronic myelogenous leukemia. Kouseisho Leukemia Study Group. Ohnishi K; Minami S; Ueda T; Nishimura M; Tsubaki K; Takemoto Y; Takeshita A; Sao H; Kageyama S; Ueda R; Ohno R Int J Hematol; 2000 Aug; 72(2):229-36. PubMed ID: 11039674 [TBL] [Abstract][Full Text] [Related]
10. Interferon alpha in the treatment of chronic myelogenous leukemia. Robak T Arch Immunol Ther Exp (Warsz); 1998; 46(6):347-53. PubMed ID: 9883313 [TBL] [Abstract][Full Text] [Related]
11. [Value of interferon-alpha in treatment of chronic myeloid leukemia]. Thaler J Acta Med Austriaca; 1993; 20(3):65-9. PubMed ID: 8368048 [TBL] [Abstract][Full Text] [Related]
12. Prolonged chronic phase in chronic myelogenous leukemia after homoharringtonine therapy. Li YF; Deng ZK; Xuan HB; Zhu JB; Ding BH; Liu XN; Chen BA Chin Med J (Engl); 2009 Jun; 122(12):1413-7. PubMed ID: 19567163 [TBL] [Abstract][Full Text] [Related]
13. Use of interferon in the treatment of chronic myelogenous leukemia. Talpaz M Semin Oncol; 1994 Dec; 21(6 Suppl 14):3-7. PubMed ID: 7992097 [TBL] [Abstract][Full Text] [Related]
14. Interferon-alfa for chronic myeloid leukemia. Baccarani M; Russo D; Rosti G; Martinelli G Semin Hematol; 2003 Jan; 40(1):22-33. PubMed ID: 12563609 [TBL] [Abstract][Full Text] [Related]
15. [Interferon-alpha in the treatment of patients with chronic myeloid leukemia]. Faber E; Jarosová M; Divoký V; Luhový M; Komenda S; Sulovská I; Hubácek J; Slezák P; Papajik T; Raida L; Heczko M; Indrák K Vnitr Lek; 1997 Jan; 43(1):13-7. PubMed ID: 9221559 [TBL] [Abstract][Full Text] [Related]
16. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data. Kantarjian HM; O'Brien S; Cortes J; Giles FJ; Rios MB; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Verstovsek S; Wierda W; Keating M; Talpaz M Cancer; 2003 Dec; 98(12):2636-42. PubMed ID: 14669283 [TBL] [Abstract][Full Text] [Related]
17. New perspectives with interferon alpha. The German CML study group experience. Hehlmann R; Ansari H; Adelberger V; Heinze B; Hossfeld K; Hochhaus A; Heimpel H Bone Marrow Transplant; 1994; 14 Suppl 3():S14-20. PubMed ID: 7697004 [No Abstract] [Full Text] [Related]
18. [Interferon-alpha therapy in chronic myeloid leukemia]. Lutz D Wien Med Wochenschr; 1993; 143(16-17):416-9. PubMed ID: 8273364 [TBL] [Abstract][Full Text] [Related]
19. The role of interferon in the treatment of chronic myelogenous leukemia in chronic phase. Guilhot F Nouv Rev Fr Hematol (1978); 1994; 36 Suppl 1():S39-46. PubMed ID: 8177714 [TBL] [Abstract][Full Text] [Related]